Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03929913 · ClinicalTrials.gov registry record · NA

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

A NA study of Functional Mitral Regurgitation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Active
Registry status
NA
Development phase
19
Enrollment target
3
Study locations

NCT03929913 is a NA study of Functional Mitral Regurgitation that is active but no longer recruiting, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 19 participants, below the 427-participant average among 5 other Functional Mitral Regurgitation trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03929913, a NA study of Functional Mitral Regurgitation, is active but no longer recruiting, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
19 participants
Enrollment target
3
Study locations

Study Summary

This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle involving the left ventricle which results in mitral valve leakage. This leakage causes heart failure (breathlessness and lack of energy especially when walking or exercising, and hospital admissions for fluid buildup). This is an early feasibility study (EFS) evaluation of special devices, permanently implanted in the heart, to perform mitral cerclage annuloplasty. Mitral cerclage annuloplasty is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The cerclage devices compress the mitral valve like a purse-string. The cerclage device has a special feature that prevents a coronary artery from getting squeezed as part of this purse-string. The protocol has been changed to allow patients who have mitral valve regurgitation despite prior Mitra-Clip treatment, and to allow patients who have symptomatic heart failure with mild mitral regurgitation.

Interventions

  • DEVICE Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)

Study Locations (3)

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Georgia

  • Emory University - Atlanta

Virginia

  • Carilion Medical Center - Roanoke

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2019-05-07
Est. Completion 2025-12-31
Phase NA

What the Registry Record Tells You About NCT03929913

The ClinicalTrials.gov registry entry for NCT03929913 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 5 other Functional Mitral Regurgitation trials with a reported enrollment target (96% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Functional Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA) is the first listed.

NCT03929913 reports 3 study locations spanning 3 distinct geographic areas - top geographies include District of Columbia, Georgia, Virginia.

Frequently Asked Questions

What is clinical trial NCT03929913 about?

NCT03929913 is a clinical study titled "NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study". This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle ...

What is the current status of trial NCT03929913?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 19 participants. The study started on 2019-05-07. Estimated completion is 2025-12-31.

What conditions does trial NCT03929913 study?

This clinical trial studies the following conditions: Functional Mitral Regurgitation.

What interventions are being tested in trial NCT03929913?

The interventions under investigation include: Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA) (DEVICE).

Who is sponsoring clinical trial NCT03929913?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03929913 being conducted?

This trial has 3 study locations across District of Columbia, Georgia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Functional Mitral Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.